Research To Practice | Oncology Videos Breast Cancer — Microlearning Activity 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dec 5, 2025
Dr. Priyanka Sharma, a leading medical oncologist specializing in breast cancer, shares insights from the ESMO 2025 meeting. She discusses the overall survival benefits of abemaciclib in high-risk localized breast cancer and the long-term efficacy of durvalumab for triple-negative cases. Dr. Sharma also delves into the competitive landscape of treatment choices, examining sacituzumab govitecan's advantages over chemotherapy. Additionally, she highlights patient-reported outcomes, emphasizing that quality of life can be maintained despite certain treatment-induced symptoms.
AI Snips
Chapters
Transcript
Episode notes
Adjuvant Abemaciclib Shows Modest OS Gain
- monarchE showed a statistically significant overall survival benefit with adjuvant abemaciclib at almost seven years of follow-up.
- The absolute OS improvement was modest (~1.8%) and reinforces using abemaciclib for patients who met the trial's high-risk criteria.
Pick CDK4/6 By Toxicity, Not Just Efficacy
- Choose between abemaciclib and ribociclib based on toxicity profiles and patient comorbidities.
- Start one drug and switch to the other if intolerance develops rather than abandoning CDK4/6 inhibitor strategy.
Trial Durations May Be Arbitrary
- Trial-prescribed durations (two vs three years) guided current practice but were arbitrarily chosen.
- Ongoing follow-up is needed to know if shorter or longer durations are optimal.